Aspen Neuroscience has expanded its ongoing Phase 1/2a clinical trial by dosing two new groups of Parkinson’s disease patients with sasineprocel (ANPD001). For the first time in the study, these participants received a new, commercial-ready formulation of the cell therapy designed to make future manufacturing and treatment…
News
A European Medicines Agency (EMA) committee is recommending approval of Hopledo (IPX203) — an oral extended-release formulation of levodopa and carbidopa sold in the U.S. under the brand name Crexont — for people with Parkinson’s disease in the European Union who experience motor fluctuations despite treatment. The EMA’s…
Parkinson’s advocacy organizations are urging the newly established National Parkinson’s Project Advisory Council to move quickly to implement the project, a U.S. strategy to prevent, diagnose, treat, and ultimately cure Parkinson’s disease. The American Parkinson Disease Association (APDA), The Michael J. Fox Foundation for Parkinson’s Research (MJFF),…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has granted $2.74 million to X-tosis to support the preclinical development of XTS001, the company’s lead candidate for the treatment of Parkinson’s disease. The funding, granted through MJFF’s Parkinson’s Disease Therapeutics Pipeline Program, will support laboratory research…
Clinical trials of UX-DA003, an experimental stem cell therapy for Parkinson’s disease developed by Unixell Biotechnology, can now begin in the U.S. following clearance from the Food and Drug Administration (FDA). The therapy aims to replace dopaminergic neurons, which are the nerve cells lost in Parkinson’s. It uses…
A new personalized, adaptive deep brain stimulation (aDBS) system developed by researchers at the University of California, San Francisco (UCSF) helped improve gait and reduce falls in a small clinical trial involving people with Parkinson’s disease. By detecting neural signals and…
A $2.5 million research grant from The Michael J. Fox Foundation (MJFF) will help expand a Phase 2 clinical study testing the experimental treatment NEU-411 in people with early Parkinson’s disease. Neuron23 will use the funds to activate four clinical sites in Israel for the Phase…
According to this year’s Parkinson’s Foundation State of the Community Survey, disease symptoms and medication knowledge are top concerns for the Parkinson’s disease community. More than half of the participants identified motor symptoms (61%), especially tremor, gait, and balance issues, and nonmotor symptoms (52%), including sleep,…
Scenic Biotech has joined the LRRK2 Investigative Therapeutics Exchange (LITE) program to study its PLA2G15 inhibitors as a potential treatment approach for Parkinson’s disease, including in people with LRRK2 gene mutations. The program is an initiative from The Michael J. Fox Foundation (MJFF) designed to identify biomarkers…
UZ Leuven and KU Leuven, two institutions in Belgium, have introduced NeuroEXPLORER PET into clinical practice. The ultra-high-resolution PET scanner, developed by United Imaging Healthcare, is designed to visualize small, deep brain regions, including those involved in Parkinson’s disease. Within the first…
Recent Posts
- ‘Thaw-and-inject’ cells given to new groups in Parkinson’s trial
- The day my uncle’s ‘I did’ proved to be louder than Parkinson’s disease
- Approval of Parkinson’s therapy urged in Europe under brand name Hopledo
- We never really know what others are facing, so let’s be kind
- Advocacy groups urge fast action on new national Parkinson’s plan